Curis

Curis EPS Growth

The EPS Growth of Curis (CRIS) as of Nov 20, 2026 is 91.49 %. In the previous year, EPS Growth was 31.15 % — a change of 193.69% (higher).

EPS Growth

91.49 %

YoY

193.69%

Last updated:

EPS Growth of Curis is 2025 91.49 % . EPS Growth of Curis was 2024 31.15 % . It decreases by 193.69% higher compared to the previous year.

The Curis EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
87.90 USD
Jan 1, 2019
1.57 USD
Jan 1, 2020
53.45 USD
Jan 1, 2021
-10.06 USD
Jan 1, 2022
93.69 USD
Jan 1, 2023
-1,213.03 USD
Jan 1, 2024
31.15 USD
Jan 1, 2025
91.49 USD
The Curis EPS Growth history
YEAREPS GrowthYoY
91.49 %+193.69%
31.15 %-102.57%
-1,213.03 %-1,394.68%
93.69 %-1,031.49%
-10.06 %-118.82%
53.45 %+3,304.05%
1.57 %-98.21%
87.90 %-131.52%
-278.86 %-2,825.07%
10.23 %-108.56%
-119.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

EPS Growth of Curis is 91.49 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Curis since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Curis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Curis

All Key Metrics — Curis